About Contact Subscribe
Health • Wellness • Medical Research

Author: MediVara Editorial Team

  • 8 Questions to Ask Before Starting Any Supplement

    The supplement aisle is built around a question you have already answered before you get there:
    which one? The more useful questions come earlier, and almost none of them are printed on
    a bottle.

    This is a checklist for deciding whether to take something at all, and how you would know if it
    were working. It is information, not medical advice, and it is not a recommendation for or against
    any supplement.

    1. What problem am I actually trying to solve?

    Write it down in one sentence, as specifically as you can. “I want to be healthier” cannot be
    evaluated. “I wake up three times a night” or “my knee hurts on stairs” can.

    This matters because a vague goal makes every product seem relevant and no product
    falsifiable.     If you cannot state what should change, you will not be able to tell whether
    anything did, and you will keep buying indefinitely.

    2. Is there evidence for this specific thing, at this dose, in people like me?

    Three separate conditions, and marketing routinely satisfies none of them while implying all of
    them.

    • This specific compound — not the food it came from. Evidence that oily
      fish is associated with better outcomes is not evidence that a fish oil capsule reproduces it.
    • At this dose — many products contain a researched ingredient at a
      fraction of the researched amount.
    • In people like me — a trial in people with a diagnosed deficiency tells
      you little about someone without one. A trial in elite athletes tells you little about a desk job.

    Our guide to glucosamine and chondroitin
    works through what this looks like when you apply it to one heavily marketed category.

    3. What does my clinician need to know?

    This is the highest-value question on the list, and the most skipped.
    Supplements are not inert, and interactions are real:

    • Blood thinners — several supplements affect clotting.
    • Antibiotics — minerals such as magnesium, calcium, zinc and iron can
      bind some antibiotics and reduce absorption.
    • Thyroid medication — absorption is affected by several minerals.
    • Surgery — surgical teams often ask patients to stop certain supplements
      in advance.
    • Kidney or liver impairment — changes how anything you take is cleared,
      which can turn a normal dose into an excessive one.
    • Pregnancy — some are recommended, others specifically avoided.

    A pharmacist can check your full list in a few minutes, usually without an appointment. Bring
    everything, including anything you would not normally think of as a medicine.

    4. Would food or a change in routine do this instead?

    Not a moral point, a practical one. Many supplemented nutrients are abundant in ordinary food,
    and for most people without a diagnosed deficiency, the dietary route is cheaper and carries fewer
    interaction questions.

    It is also worth asking whether the thing you are treating is nutritional at all. Fatigue, poor
    sleep and low mood have many causes, and most of them do not respond to a capsule.

    5. How would I know whether it worked?

    Decide this before you start, because deciding afterwards is how everyone concludes it
    worked.

    • Write down a baseline. A number if possible — pain out of 10, hours
      slept, times waking — plus one specific activity you struggle with.
    • Set a review date. Most trials run for months, so a week tells you nothing.
      Eight to twelve weeks is a reasonable default.
    • Change one thing at a time. Starting a supplement, a new bedtime and a gym
      membership in the same week means you learn nothing about any of them.
    • Expect regression to the mean. People usually start something when symptoms
      are at their worst, and symptoms that fluctuate tend to improve afterwards regardless. That
      improvement is easy to misattribute.

    6. What am I actually paying, and for how long?

    Cost per serving, not per capsule — if a serving is three capsules, a 90-count
    bottle is a 30-day supply. Then multiply by the months you intend to continue, because this is a
    recurring cost, not a purchase.

    If it is a subscription, find the cancellation path before you sign up rather than when you want
    to leave.

    7. Is the product what it says it is?

    In the US, supplements are not reviewed by the FDA for safety or effectiveness before sale, so
    independent verification matters. Look for marks from organisations such as USP, NSF International
    or ConsumerLab.

    Be precise about what that buys you: certification generally confirms the product contains what
    the label claims, without specified contaminants. It says nothing about whether the
    ingredient works.     Our guide to
    reading a supplement label
    covers the rest of the panel, including the one place labels are designed to hide the dose.

    8. What would make me stop?

    Agree the exit in advance, or there will not be one.

    • Nothing has changed by the review date.
    • Side effects appear — digestive upset is the most common.
    • Your clinician identifies an interaction.
    • The cost stops making sense for an effect you cannot detect.

    “I might as well keep taking it” is how a trial becomes a subscription.

    Marketing patterns that should slow you down

    None proves a product is bad. All are reasons to check more carefully.

    • A named condition it claims to treat. Supplements legally cannot claim to
      diagnose, treat, cure or prevent disease. A product doing so is breaking the rules it operates
      under.
    • Urgency. Countdowns and disappearing discounts are sales mechanics. Your
      nutritional status does not have a deadline.
    • Proprietary blends where the actives are, which makes dose verification
      impossible.
    • Testimonials instead of trials. A compelling story is not evidence, and the
      people it did not work for do not appear.
    • “Doctor formulated.” Not a regulated term, and not the same as tested.
    • Attacking mainstream medicine to establish credibility.
    • A quiz that recommends products. The output was decided before your answers.

    When a supplement is the wrong tool entirely

    If you are taking something to address a symptom, the more useful question is what is causing
    the symptom. Persistent fatigue, pain, breathlessness, or low mood are reasons to see a
    clinician    , not reasons to optimise a purchase. Self-treating can also delay a diagnosis
    that matters.

    Supplements are best understood as filling a specific, identified gap — not as a general
    upgrade to a healthy body.

    The short version

    1. State the problem in one sentence.
    2. Check the evidence for this compound, at this dose, in people like you.
    3. Ask a pharmacist about interactions — bring your full list.
    4. Consider whether food or a routine change does the same job.
    5. Write a baseline and set a review date before starting.
    6. Work out the real monthly cost.
    7. Look for third-party testing.
    8. Decide in advance what would make you stop.

    Free: the Supplement Evaluation Checklist

    16 checks for deciding whether a supplement is worth buying — serving size, proprietary blends, third-party testing, and what to ask a pharmacist. Several of them end with don’t buy this. No email required.

    Open the checklist →

    Sources

    MediVara publishes health journalism. This article is not medical advice and is not reviewed
    by a licensed clinician. Do not start, stop or change any supplement or medication without speaking
    to a qualified healthcare professional who knows your history and your current prescriptions.

  • Supplement Evaluation Checklist

    A free checklist for deciding whether a supplement is worth
    buying.     No email required. Built to be used standing in a shop or on a checkout page, not
    read as an article.

    Most supplement content is written by people selling supplements. This is the opposite: a set of
    checks that frequently end with “don’t buy this.” That is a legitimate outcome, and it is
    the one the industry’s own content never reaches.

    This is information, not medical advice. It does not diagnose, treat or prevent anything.

    Before you look at any product

    ☐ 1. Write the problem in one sentence

    Specific enough to be wrong. “I want to be healthier” cannot be evaluated.
    “I wake up three times a night” or “my knee hurts going downstairs”
    can.

    Why it matters: a vague goal makes every product seem relevant and none of them
    falsifiable. If you cannot say what should change, you will never be able to tell whether anything
    did — and you will keep buying.

    ☐ 2. Ask whether this is a nutrition problem at all

    Fatigue, poor sleep, low mood and aching joints have many causes. Most do not respond to a
    capsule.

    Stop here if: the symptom is persistent, worsening, or new. That is a clinician
    question, and a supplement can delay an answer that matters.

    ☐ 3. Check whether food does this

    Many supplemented nutrients are abundant in ordinary food, and for people without a diagnosed
    deficiency the dietary route is cheaper with fewer interaction questions.

    Checking the evidence

    ☐ 4. Evidence for this compound, at this dose, in people like you

    Three separate conditions. Marketing routinely satisfies none while implying all three.

    • This compound — not the food it came from. Evidence that oily fish is
      associated with better outcomes is not evidence that a capsule reproduces it.
    • This dose — many products contain a researched ingredient at a fraction of the
      researched amount.
    • People like you — a trial in people with a diagnosed deficiency says little
      about someone without one.

    ☐ 5. Check who paid for the research

    Across supplement literature, industry-funded trials tend to report more favourable results than
    independently funded ones. Large independent trials deserve more weight.

    Reading the label

    ☐ 6. Serving size — the most misread line

    Every number on the panel is per serving, not per capsule. If a serving is three
    capsules, a bottle of 90 lasts 30 days, not 90, and the advertised dose requires
    taking all three.

    This single line changes both the real dose and the real cost per day.

    ☐ 7. Is there a proprietary blend?

    A blend lists one combined weight without disclosing how much of each ingredient is present.
    Ingredients must appear in descending order by weight — that is all you get.

    Red flag: if the active ingredients sit inside a blend, you cannot
    verify the dose of anything    , and you cannot compare the product to any other.

    ☐ 8. Check the form of the ingredient

    Magnesium oxide and magnesium citrate are both magnesium and differ meaningfully in absorption.
    Where research supports an ingredient, it usually supports a specific form.

    ☐ 9. Look for third-party testing

    Marks from USP, NSF International or ConsumerLab.

    Know exactly what this buys you: certification generally confirms the product
    contains what the label says, without specified contaminants. It does not mean the
    ingredient works.     Quality and efficacy are separate questions, and marketing blurs them.

    ☐ 10. Find the disclaimer

    US supplements are not reviewed by the FDA for effectiveness before sale. A structure/function
    claim must carry: “This statement has not been evaluated by the Food and Drug Administration.
    This product is not intended to diagnose, treat, cure, or prevent any disease.”

    Read that as an instruction, not boilerplate. A product that could claim more
    would be claiming more.

    Before you pay

    ☐ 11. Ask a pharmacist about interactions

    The highest-value five minutes in this entire process, and the most skipped.
    Usually no appointment needed. Bring your full list.

    Particularly relevant with: blood thinners · antibiotics · thyroid medication · upcoming surgery
    · kidney or liver impairment · pregnancy.

    ☐ 12. Work out the real monthly cost

    Cost per serving, not per capsule (see #6), multiplied by the months you intend
    to continue. This is a recurring cost, not a purchase. If it is a subscription, find the
    cancellation path before signing up.

    ☐ 13. Write your baseline down

    A number if possible — pain out of 10, hours slept, times waking — plus one specific activity you
    struggle with.

    Memory reconstructs improvement that did not happen. Without a written baseline
    you will not be able to judge the outcome honestly.

    ☐ 14. Set a review date before you start

    Most trials run for months, so a week tells you nothing. Eight to twelve weeks
    is a reasonable default. Write the date down.

    ☐ 15. Change one thing at a time

    Starting a supplement, a new bedtime and a gym membership in the same week means you learn
    nothing about any of them.

    ☐ 16. Decide now what would make you stop

    Nothing changed by the review date · side effects appear · your clinician finds an interaction ·
    the cost stops making sense.

    “I might as well keep taking it” is how a trial becomes a subscription.

    Expect regression to the mean

    This is the single biggest reason people believe a supplement worked, and it is almost never
    mentioned.

    People start something when symptoms are at their worst. Symptoms that fluctuate
    tend to improve afterwards regardless of what was taken. That improvement feels like evidence and
    is not.

    It is why a written baseline and a fixed review date matter more than any individual check above.

    Marketing patterns that should slow you down

    None proves a product is bad. All are reasons to look harder.

    • A named condition it claims to treat — supplements legally cannot claim to
      diagnose, treat, cure or prevent disease. A product doing so is breaking its own rules.
    • Urgency or countdowns — your nutritional status does not have a deadline.
    • Proprietary blends hiding the actives.
    • Testimonials instead of trials — the people it did not work for do not appear.
    • “Doctor formulated” — not a regulated term, and not the same as tested.
    • Attacking mainstream medicine to establish credibility.
    • A quiz that recommends products — the output was decided before your answers.

    The one-line version

    Know what problem you are solving · check the dose against the research, not the
    marketing · read the serving size · ask a pharmacist about interactions · write a baseline · set a
    review date · decide in advance what would make you stop.

    Sources

    MediVara publishes health journalism. This checklist is not medical advice and is not
    reviewed by a licensed clinician. Do not start, stop or change any supplement or medication without
    speaking to a qualified healthcare professional who knows your history and your prescriptions.

  • How to Read a Supplement Label

    A supplement label is a legal document with a marketing department attached. Most of what catches
    your eye on the front is the marketing. Almost everything that determines whether the product is
    worth buying is on the back, in small type, and is genuinely confusing on purpose in a few specific
    places.

    This is how to read one. It is information, not medical advice, and it is not a recommendation
    to take or avoid any supplement.

    It pairs with our checklist on
    questions to ask before buying a health package
    — the same evaluation habit, applied to a different purchase.

    First: what the label is allowed to claim

    In the United States, dietary supplements are regulated under the Dietary Supplement Health and
    Education Act of 1994. The practical consequence is the single most important thing to understand
    about the entire category:

    Supplements are not reviewed by the FDA for safety or effectiveness before they go on
    sale.     Manufacturers are responsible for ensuring their own products are safe and that
    claims are truthful. FDA action generally comes after a product is on the market.

    That is not a scandal, and it does not mean supplements are dangerous. It means the burden of
    evaluation sits with you in a way it does not with a prescription medicine.

    The disclaimer that tells you what kind of claim you are reading

    If a label says something like “supports immune health” or “promotes joint comfort”, it is
    making a structure/function claim. Those must carry this disclaimer, usually in
    small print:

    “This statement has not been evaluated by the Food and Drug Administration. This
    product is not intended to diagnose, treat, cure, or prevent any disease.”

    Treat that disclaimer as a reading instruction, not legal boilerplate. It is
    telling you that the claim above it has not been assessed by anyone. A product that could claim
    more would be claiming more.

    The Supplement Facts panel, line by line

    Serving size — the line people misread most

    Check this before anything else, because every other number on the panel is per
    serving, not per capsule.

    If the serving size is “3 capsules”, then a bottle of 90 is a 30-day supply, not 90 days, and
    the impressive dose on the panel requires taking three. This single line changes both the real cost
    per day and the real dose, and it is the most common misreading in the category.

    Amount per serving

    The dose. The question worth asking is not “is this a lot?” but “is this the amount that
    was actually studied?”     Plenty of products contain a real ingredient at a fraction of the
    dose used in the research that made it popular — which is legal, accurate, and useless.

    % Daily Value, and why it is often blank

    %DV tells you how much of an established daily reference intake one serving provides. Two things
    to know:

    • Many supplement ingredients — botanicals, probiotics, most “novel” compounds — have
      no established Daily Value, so the column shows a dagger symbol and a footnote
      reading “Daily Value not established.” That is not a red flag. It means no reference intake exists.
    • A very high %DV is not automatically better. Some nutrients have an established upper limit
      above which risk rises. Fat-soluble vitamins in particular accumulate.

    Proprietary blends — the one place the label is designed to hide something

    A “proprietary blend” lists a total weight for a group of ingredients without disclosing how much
    of each. You might see “Recovery Blend, 1,200 mg” followed by eight ingredients.

    Legally, the ingredients must be listed in descending order by weight. That is the only
    information you get. The blend could be 1,150 mg of the cheapest component and trace amounts of the
    rest — a practice common enough to have a name: fairy dusting.

    If the active ingredients are in a proprietary blend, you cannot verify the dose of
    anything.     There are legitimate formulation reasons for blends, but the effect is that the
    comparison you are trying to make becomes impossible.

    Ingredient form

    The specific chemical form is on the label and it can matter. Magnesium oxide and magnesium
    citrate are both magnesium; they differ meaningfully in absorption. Folate and folic acid are not
    interchangeable for everyone. “Vitamin E” covers several compounds.

    When research supports an ingredient, it usually supports a specific form at a specific
    dose    . The label tells you which one you have.

    Other ingredients

    Below the panel. Fillers, binders, capsule material, flow agents, colours. This is where you
    find gelatin if you avoid it, and where allergen statements appear. Usually unremarkable, worth
    thirty seconds.

    Third-party testing marks

    Because nobody verifies contents before sale, independent verification is the main quality
    signal available. Look for marks from organisations such as USP, NSF
    International     or ConsumerLab.

    Be precise about what these mean. Third-party certification generally verifies that the
    product contains what the label says, in the stated amount, without specified contaminants.

    It does not mean the ingredient works. A certified mark on a useless supplement
    certifies that you are accurately receiving a useless supplement. It solves the quality question,
    not the efficacy question — and those are separate.

    What is not on the label at all

    • Interactions with your medications. Not on the label. This is a pharmacist
      conversation, and it is the highest-value 5 minutes available in this whole process.
    • Whether you need it. A supplement corrects a deficiency or it does not. Most
      labels imply a need the product cannot establish.
    • Evidence quality. “Clinically studied” can describe one small industry-funded
      trial.
    • Cost per effective dose. The price on the shelf divided by servings, not by
      capsules — see serving size above.

    A two-minute label check

    1. Serving size — how many capsules is one serving, and how many days does the
      bottle actually last?
    2. Dose vs research — is the amount per serving what studies used?
    3. Proprietary blend? — if the actives are hidden inside one, you cannot compare
      it to anything.
    4. Form — is it the form the evidence supports?
    5. Third-party mark — USP, NSF or equivalent.
    6. Disclaimer — confirms you are reading an unevaluated structure/function claim.
    7. Cost per serving — not per capsule.
    8. Interactions — ask a pharmacist, especially with blood thinners, blood
      pressure medication, thyroid medication, or before surgery.

    When the label is the wrong question

    If you are taking a supplement to address a symptom, the more useful question is what is causing
    the symptom. Persistent fatigue, pain, or low mood are reasons to see a clinician, not reasons to
    optimise a purchase.

    And if a product’s marketing promises a cure, guarantees a result, or urges you to buy before a
    deadline, the label will not rescue it. Claims that strong are not permitted for a reason.

    For a worked example of applying all of this to one popular category, see our review of the
    evidence on joint health and cartilage.

    Free: the Supplement Evaluation Checklist

    16 checks for deciding whether a supplement is worth buying — serving size, proprietary blends, third-party testing, and what to ask a pharmacist. Several of them end with don’t buy this. No email required.

    Open the checklist →

    Frequently asked questions

    Does the FDA approve dietary supplements before they are sold?

    No. Under the Dietary Supplement Health and Education Act of 1994, supplements are not reviewed
    by the FDA for safety or effectiveness before going on sale. Manufacturers are responsible for
    ensuring their own products are safe and that claims are truthful, and FDA action generally comes
    after a product is already on the market. This is the single most important difference between a
    supplement and a prescription medicine.

    What does a proprietary blend mean on a label?

    It means a group of ingredients is listed with one combined weight, without disclosing how much
    of each is present. Ingredients must appear in descending order by weight, and that is the only
    information you get. The blend could consist mostly of the cheapest component with trace amounts of
    the rest. If the active ingredients sit inside a proprietary blend, you cannot verify the dose of
    anything or compare the product to another.

    What does %DV mean, and why is it sometimes blank?

    Percent Daily Value tells you how much of an established daily reference intake one serving
    provides. It is blank, shown as a dagger with a footnote reading “Daily Value not established”, for
    ingredients that have no reference intake, which includes most botanicals and probiotics. That is
    not a warning sign. A very high %DV is also not automatically better, since some nutrients have
    upper limits above which risk rises.

    Do third-party certification marks mean a supplement works?

    No. Marks from organisations such as USP, NSF International or ConsumerLab generally verify that
    the product contains what the label says, in the stated amount, without specified contaminants.
    That addresses quality, not effectiveness. A certification on an ineffective supplement confirms
    you are accurately receiving an ineffective supplement. Quality and efficacy are separate
    questions.

    Why does serving size matter so much?

    Because every other number on the panel is per serving, not per capsule. If a serving is three
    capsules, a bottle of 90 lasts 30 days rather than 90, and the dose shown requires taking all
    three. This one line changes both the real daily dose and the real cost per day, and it is the most
    commonly misread part of a supplement label.

    Sources

    MediVara publishes health journalism. This article is not medical advice and is not reviewed
    by a licensed clinician. Do not start, stop or change any supplement or medication without speaking
    to a qualified healthcare professional who knows your history and your current prescriptions.

  • Glucosamine and Chondroitin: What the Evidence Shows

    Glucosamine and chondroitin are among the most widely sold supplements in the United States, and
    almost all of that spending is for one reason: joint pain, usually knee osteoarthritis.

    The evidence behind them is weaker than the marketing suggests, and more interesting than a flat
    “they don’t work.” This is what the research actually found, where it is genuinely uncertain, and
    what has stronger evidence for the same problem. It is information, not medical advice.

    For the wider picture of how joints wear and what protects them, see our guide to
    protecting cartilage and preventing arthritis.

    What they are

    Both occur naturally in cartilage, the tissue that cushions the ends of bones inside a joint.

    • Glucosamine is a building block used to make and repair cartilage. Supplements
      are usually made from shellfish shells, or produced by fermentation.
    • Chondroitin helps cartilage hold water, which is part of what lets it resist
      compression. Supplements are typically derived from animal cartilage.

    The reasoning behind taking them is intuitive: cartilage wears down in osteoarthritis, these are
    components of cartilage, so supplying more might help rebuild it. That logic is reasonable
    and it is exactly what the trials were designed to test.     Being plausible is not the same as
    being effective, which is why the trials matter more than the rationale.

    What the evidence shows

    The most important single study is GAIT — the Glucosamine/chondroitin
    Arthritis Intervention Trial — funded by the US National Institutes of Health and published in
    the New England Journal of Medicine in 2006. It enrolled roughly 1,580 people with knee
    osteoarthritis and compared five groups over 24 weeks: glucosamine alone, chondroitin alone, both
    together, celecoxib (a prescription anti-inflammatory), and placebo.

    The headline result: neither glucosamine nor chondroitin, alone or combined, performed
    significantly better than placebo     for the trial’s main measure of knee pain. Celecoxib did.

    Independent systematic reviews since then have generally pointed the same way, particularly for
    the question of whether these supplements slow cartilage loss. Evidence for a
    structural benefit — actually preserving the joint — is weak.

    The part that is genuinely uncertain

    Honest reporting has to include this. Within GAIT, a subgroup with moderate-to-severe
    knee pain     did appear to respond better to the glucosamine-plus-chondroitin combination
    than to placebo.

    That finding is real, and it is also exploratory: the subgroup was small, it was
    one of several analysed, and subgroup results that were not the trial’s primary question are the
    classic way a false signal appears in otherwise negative research. It was never confirmed as a
    definitive result.

    So the accurate summary is not “proven to work for severe pain.” It is: a possible signal in
    one subgroup that has not been confirmed, inside a trial that was otherwise negative.

    Why study results disagree

    Two real complications explain some of the inconsistency between studies:

    • Form matters. Glucosamine sulfate and glucosamine hydrochloride
      are not identical, and trials have used both. Some European trials of a specific patented glucosamine
      sulfate preparation reported more positive results than independent trials using other forms.
    • Funding source matters. Across this literature, industry-funded trials have
      tended to report more favourable results than independently funded ones. This is a well-documented
      pattern in supplement research generally, and it is a reason to weight large independent trials such
      as GAIT more heavily.

    Osteoarthritis pain also fluctuates on its own and responds strongly to placebo, which makes small
    or uncontrolled studies particularly unreliable here.

    Safety and cost

    These supplements are generally well tolerated. Reported side effects are usually mild and
    digestive. Some specific points worth knowing:

    • Blood thinners. There are reports of glucosamine interacting with warfarin and
      affecting clotting. If you take an anticoagulant, this is a conversation with your clinician before
      you start, not after.
    • Shellfish. Most glucosamine comes from shellfish shells. Shellfish allergy is
      typically to proteins in the meat rather than the shell, but if you have one, raise it.
    • Blood sugar. Effects on glucose metabolism have been investigated; if you have
      diabetes, worth mentioning.
    • Regulation. In the US, supplements are not reviewed by the FDA for effectiveness
      before sale the way medicines are. Manufacturers are responsible for their own quality control, so
      actual content can vary between products. Third-party testing marks are one imperfect signal.

    On cost: this is an ongoing monthly expense, usually taken for months before any judgement is
    possible. That is the real trade-off — not risk of harm, but sustained spending on something
    whose average effect in the largest independent trial was not distinguishable from placebo.

    What has stronger evidence for the same problem

    This is the part most supplement coverage leaves out. For knee osteoarthritis, several
    interventions have a stronger evidence base than glucosamine or chondroitin:

    • Exercise. Structured strengthening and low-impact aerobic exercise is
      consistently among the best-supported treatments. It is also counter-intuitive — people often
      assume a painful joint should be rested, when appropriate loading generally helps.
    • Weight management. For people carrying excess weight, reducing load on the knee
      has a substantial evidence base for pain improvement.
    • Physical therapy. Supervised programmes address the specific mechanics of your
      joint rather than a general protocol.
    • Clinician-guided pain management. Including topical and oral options your
      clinician can match to your history.

    None of these is as easy as a capsule, which is a fair part of why supplements sell. But if the
    goal is the outcome rather than the convenience, this is where the evidence is strongest.

    If you are still considering trying it

    This is a reasonable choice for some people, and it is not the same as being misled. If you do:

    • Tell your clinician first, especially if you take a blood thinner.
    • Decide your review date in advance. Most trials ran for several months. Pick a
      point — say 8 to 12 weeks — at which you will honestly assess whether anything changed.
    • Write down your baseline. Pain on a 0–10 scale, and one specific thing you
      struggle with, such as stairs. Memory reconstructs improvement that did not happen.
    • Change one thing at a time. Starting a supplement and an exercise programme in
      the same week means you will never know which did anything.
    • Stop if nothing changes. The review date only works if you act on it.
    • Do not substitute it for exercise, weight management or prescribed treatment.

    Questions worth asking your clinician

    • Is my joint pain osteoarthritis, or something else that would be treated differently?
    • Given my medications, is there any interaction risk?
    • What has the strongest evidence for my specific situation?
    • Would physical therapy be appropriate, and can I be referred?
    • How would we tell whether something is genuinely working?

    What to take from this

    • GAIT, the largest independent trial, found no significant benefit over placebo
      for knee osteoarthritis pain overall.
    • A moderate-to-severe pain subgroup showed a possible signal, but it was
      exploratory and unconfirmed.
    • Evidence that these supplements preserve cartilage structure is weak.
    • They are generally well tolerated; the main issues are the warfarin interaction
      and ongoing cost.
    • US supplements are not reviewed for effectiveness before sale.
    • Exercise, weight management and physical therapy have stronger evidence for the
      same problem.
    • Persistent or worsening joint pain warrants a clinician, not a supplement aisle.

    The same evidence-first approach applies to buying decisions generally — our checklist on
    questions to ask before you buy a health package
    covers the pattern.

    Free: the Supplement Evaluation Checklist

    16 checks for deciding whether a supplement is worth buying — serving size, proprietary blends, third-party testing, and what to ask a pharmacist. Several of them end with don’t buy this. No email required.

    Open the checklist →

    Frequently asked questions

    Do glucosamine and chondroitin actually work for knee pain?

    In GAIT, the largest independent trial, neither supplement alone nor the two combined performed
    significantly better than placebo for knee osteoarthritis pain over 24 weeks. Celecoxib, a
    prescription anti-inflammatory included in the same trial, did. A subgroup with moderate-to-severe
    pain appeared to respond to the combination, but that finding was exploratory and was never
    confirmed.

    How long should I take glucosamine before deciding whether it helps?

    Most trials ran for several months, so a few weeks tells you little. Decide your review date
    before you start, commonly 8 to 12 weeks, and write down your baseline first: pain on a 0 to 10
    scale plus one specific activity you struggle with. Memory tends to reconstruct improvement that
    did not happen, which is part of why uncontrolled self-assessment is unreliable here.

    Is glucosamine safe to take with blood thinners?

    Raise it with your clinician before starting. There are reports of glucosamine interacting with
    warfarin and affecting clotting. This is the single most important safety conversation for this
    supplement, and it belongs before the first dose rather than after.

    Are glucosamine sulfate and glucosamine hydrochloride the same?

    No, and the difference is one reason study results disagree. Trials have used both forms. Some
    European trials of a specific patented glucosamine sulfate preparation reported more positive
    results than independent trials using other forms. Across this literature, industry-funded trials
    have also tended to report more favourable results than independently funded ones.

    What has better evidence than supplements for knee osteoarthritis?

    Structured exercise, particularly strengthening and low-impact aerobic work, is consistently
    among the best-supported treatments. Weight management has a substantial evidence base for people
    carrying excess weight, because it reduces load on the joint. Supervised physical therapy addresses
    the mechanics of your specific joint. None is as convenient as a capsule, which is part of why
    supplements sell.

    Sources

    • Clegg DO et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee
      osteoarthritis       (GAIT). New England Journal of Medicine, 2006 —
      NEJM
    • National Center for Complementary and Integrative Health (NIH) —
      Glucosamine and Chondroitin for Osteoarthritis
    • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIH) —
      Osteoarthritis
    • Centers for Disease Control and Prevention —
      Arthritis

    MediVara publishes health journalism. This article is not medical advice and is not reviewed
    by a licensed clinician. Do not start, stop or change any supplement or medication without speaking
    to a qualified healthcare professional who knows your history.

  • Asthma Clinical Trials: How to Decide Whether to Join

    If you have asthma that is not well controlled, you have probably seen the adverts: a short form,
    a promise that researchers in your area are looking for people like you, and a request for your
    phone number. Asthma is one of the most heavily recruited conditions in US clinical research, and
    the recruitment industry around it is substantial.

    That does not make it illegitimate. Asthma trials are real, they are common, and for some people
    joining one is a reasonable decision. But the adverts are marketing, and they are not where the
    decision should be made. This article covers why asthma is recruited so heavily, what joining
    typically involves, and how to check that a specific study is real before you share anything.

    It is information, not medical advice. MediVara does not screen, endorse or recommend
    any trial or recruitment service.

    Why asthma trials recruit so aggressively

    Three things make asthma unusually attractive to researchers, and they explain the volume of
    advertising.

    The population is large. Current asthma affects around 7.7% of the US
    population, so a great many people are potentially eligible for something.

    A lot of it is not well controlled. Half of children with current asthma had
    uncontrolled asthma, and close to four in ten adults with asthma reported an attack in 2021. Poor
    control is precisely what new treatments are trying to address, so trials actively seek people whose
    current regimen is not working well.

    It is measurable. Lung function can be quantified, symptoms and rescue-inhaler
    use can be counted, and exacerbations are countable events. Conditions that produce clean numbers
    are easier to study, which means more studies get run.

    The result is genuine demand for participants — and a recruitment industry built to meet
    it. Both things are true at once.

    What an asthma trial usually involves

    Specifics vary enormously by study, and the only reliable source is the protocol for the study in
    front of you. In general terms, expect:

    • A screening visit before enrolment, typically including lung-function testing.
      Many people are screened and not enrolled.
    • A run-in period in some studies, during which your existing treatment is
      standardised before anything changes.
    • Regular visits — often more frequent than your ordinary asthma care.
    • Spirometry at most visits.
    • A daily diary of symptoms and rescue-inhaler use.
    • Rules about your other medication, which is the part most worth understanding
      in detail before agreeing.

    That last point deserves emphasis. Ask exactly what happens to your current treatment, whether
    any of it is paused or replaced, and what you are to do if your asthma worsens during the study.
    A trial should have a defined answer for that, and you should know it before you enrol.

    The placebo question, specifically for asthma

    This is the question people most want answered and most hesitate to ask.

    Ask two things, separately. Is there a placebo group? And what does that group
    receive?     In many trials for conditions where withholding treatment would be unsafe, the
    comparison group receives standard care with placebo added to it, rather than placebo instead of
    treatment. That is a materially different proposition from going untreated, and the answer should
    be stated plainly in the consent discussion.

    Also ask what the rules are for using your rescue inhaler during the study, and what triggers the
    study team to take you out of it if your asthma deteriorates.

    Checking that a study is real

    Many asthma trials recruit through third-party websites and ad campaigns. Some are run by
    legitimate recruitment firms working for a sponsor. A polished page tells you nothing either way,
    and the site is not the study.

    1. Ask for the NCT number. Every registered study has one. A legitimate recruiter
      can provide it.
    2. Look it up on ClinicalTrials.gov
      yourself      , by typing the address rather than following a link you were sent.
    3. Compare the advert against the registry record — condition, phase,
      eligibility criteria, recruiting status, sponsor and listed locations.
    4. Check a site near you is genuinely recruiting.
    5. Ask what happens to your data if you are screened out. A recruitment form is a
      disclosure of health information. You are entitled to know whether it is retained, shared or used
      for marketing.

    Treat these as warning signs: no NCT number available on request, guaranteed acceptance, any
    request for payment to participate, pressure to decide immediately, or a claim that the study will
    cure your asthma. Legitimate studies do not charge participants, and research does not make
    guarantees.

    Our general guide to how clinical trials work, including consent, eligibility and IRB oversight,
    covers the verification process in more detail.

    Questions specific to an asthma study

    • What is being tested, and what phase is the study?
    • What happens to my current controller and reliever medication?
    • Is there a placebo arm, and what does that arm receive?
    • What are the rules for rescue-inhaler use during the study?
    • What happens if my asthma gets worse — who do I contact, at any hour?
    • How many visits, how long is each, and over what total period?
    • Will I have spirometry, and will I be told my results?
    • Who pays for what? Research procedures are commonly covered by the sponsor, but routine care
      may still be billed.
    • Are travel and time reimbursed?
    • What happens at the end — can I continue the treatment if it helped?
    • Will my usual asthma clinician be informed that I am enrolled?

    That last question is easy to skip and worth asking. Someone is managing your asthma; a study is
    a significant change to it.

    Deciding, honestly

    The reasonable reasons to join are access to something not otherwise available, closer monitoring
    than routine care usually provides, and contributing to knowledge that helps other people with
    asthma later. All three are real.

    Against that: the treatment may not work, you may be in the comparison arm, there may be unknown
    side effects, and the visit schedule is usually more demanding than ordinary care. Declining a trial
    is a completely reasonable decision, and being screened out is common and not a judgement about you.

    Before enrolling, discuss it with the clinician who manages your asthma. They
    know your control history, your current regimen and how a study’s medication rules would interact
    with it — none of which a recruitment form can see.

    Before you look at trials at all

    If the reason you are considering a study is that your asthma is not well controlled, there are
    two things worth ruling out first, because both are common and both are fixable.

    Inhaler technique. More than 8 in 10 US patients with obstructive lung disease
    make at least one technique error, and technique decays over time even after correct teaching. If a
    share of every dose is not reaching your lungs, the medication will look less effective than it is.
    This is worth checking with a pharmacist
    before concluding that your treatment has failed.

    Whether your plan has been reviewed recently. Asthma guidance has changed
    meaningfully in recent years. A regimen that has not been revisited in a long time may not reflect
    current practice, and what “controlled” should look like
    is a reasonable thing to raise at your next appointment.

    A clinical trial is a legitimate option. It should not be the first thing tried when simpler
    explanations have not been ruled out.

    Sources

    MediVara publishes health journalism. This article is not medical advice, is not reviewed by
    a licensed clinician, and MediVara does not screen, endorse or recommend any clinical trial or
    recruitment service. Decisions about trial participation and about asthma treatment belong with a
    qualified healthcare professional.

    Frequently asked questions

    Are asthma clinical trials legitimate?

    Asthma trials are real and common, and asthma is one of the most heavily recruited conditions in US clinical research. That recruitment volume is driven by genuine factors: a large population, a high proportion of poorly controlled disease, and outcomes that are easy to measure. But an advert is marketing, and the site running it is not the study. Verify any specific study on ClinicalTrials.gov using its NCT number before sharing your details.

    Will I be given a placebo in an asthma trial?

    It depends on the study design, and you should ask two separate questions: whether there is a placebo group, and what that group actually receives. In many trials for conditions where withholding treatment would be unsafe, the comparison group receives standard care with placebo added to it rather than placebo instead of treatment. Also ask what the rules are for rescue-inhaler use and what happens if your asthma worsens during the study.

    Does it cost money to join an asthma trial?

    Legitimate studies do not charge participants to take part, and any request for payment is a serious warning sign. Research procedures are commonly covered by the sponsor, but routine care costs may still be billed to you or your insurer, so ask specifically who pays for what before enrolling.

    What happens to my current asthma medication during a trial?

    This is the part most worth understanding in detail before agreeing. Ask exactly what happens to your current controller and reliever, whether any of it is paused or replaced, what the rules are for rescue-inhaler use, and what you should do if your asthma worsens. A study should have a defined answer for each, and you should know it before you enrol.

    Should I try anything else before looking at trials?

    If the reason you are considering a study is poor control, two common and fixable things are worth ruling out first. The first is inhaler technique: more than 8 in 10 US patients with obstructive lung disease make at least one technique error, and technique decays over time even after correct teaching. The second is whether your treatment plan has been reviewed recently, since asthma guidance has changed meaningfully in recent years.

    Related reading

  • Asthma Control: What “Controlled” Actually Means

    There is a word that does a lot of quiet work in asthma care, and most people are never told what
    it actually means. The word is controlled.

    Controlled asthma is not asthma that has gone away. It is asthma that is not limiting your life:
    few symptoms, little rescue-inhaler use, no night-time waking, no restriction on activity. It is a
    measurable target, and it is the target your treatment is aimed at — which means it is also
    the thing you can check yourself.

    Plenty of people are living with uncontrolled asthma and have adjusted to it, because the
    decline was gradual. Half of children with current asthma had uncontrolled asthma
    in US surveillance data. This article covers what control means, how triggers work, and what to
    bring to an appointment. It is information, not medical advice.

    Asthma in the US, in numbers

    The scale is larger than most people assume, and the trend is not uniform.

    • Current asthma prevalence in the general US population rose from 7.4% in 2001 to 7.7%
      in 2021      .
    • About 6.5% of children under 18 currently have asthma (2024).
    • Prevalence increased among adults from 2013 through 2021, while it
      decreased among children from 2010 through 2021.
    • Asthma attacks among adults with asthma fell from 53.8% in 2001 to 39.6% in
      2021       — real improvement, and still close to four in ten.

    The burden is not evenly shared. Current asthma prevalence among non-Hispanic Black
    children was 12.5%, compared with 5.7% among non-Hispanic White children     — more than
    double. Disparities of that size reflect differences in housing quality, air pollution exposure and
    access to care, not differences in biology.

    What “controlled” actually means

    Control is assessed over roughly the past four weeks, and it is about function, not just
    symptoms. The questions clinicians work from look like this:

    • Have you had daytime symptoms more than twice a week?
    • Have you woken at night because of your asthma?
    • Have you needed your rescue inhaler more than twice a week for symptoms?
    • Has your asthma limited any activity — exercise, work, stairs, play?

    The more of these that are true, the less controlled the asthma. Night-time waking and
    rising rescue-inhaler use are the two signals most worth taking seriously    , because both
    tend to be dismissed as normal by the person experiencing them.

    An important distinction: control is how you are doing now; severity is how
    much treatment it takes to get you there. Someone on substantial treatment with no symptoms has
    severe but well-controlled asthma. Someone on minimal treatment waking twice a week has mild but
    poorly controlled asthma. The second situation is the one that needs attention.

    Reliever and controller are not interchangeable

    This is the most consequential thing to understand about asthma medication, described here in
    general terms only — your own regimen is a matter for your clinician.

    • Relievers (rescue inhalers) act quickly on symptoms. They are for episodes.
    • Controllers (typically inhaled corticosteroids) reduce the underlying airway
      inflammation over time. They work whether or not you feel symptoms today, which is exactly why
      people stop taking them.

    Because the reliever produces an immediate, obvious effect and the controller does not, it is
    easy to drift into relying on the reliever. That drift is itself the warning sign:
    needing a rescue inhaler often means the underlying inflammation is not controlled,
    and treating it with more reliever addresses the symptom rather than the cause.

    If control does not improve after technique and treatment have both been reviewed, a clinical trial is one option some people consider. Guidance in this area has changed meaningfully in recent years. If your plan has not been
    reviewed in a long time, that is a reasonable thing to raise. Do not change, stop or delay
    any prescribed medication on your own.

    Triggers: yours are not everyone’s

    Trigger lists are published everywhere, and they are useful mainly as a menu to test against your
    own experience. Common categories include:

    • Allergens — dust mites, pet dander, cockroach allergen, mould, pollen.
    • Irritants — tobacco smoke, wood smoke, air pollution, strong fragrances,
      cleaning products.
    • Infections — respiratory viruses are among the most common triggers of
      worsening in both children and adults.
    • Exercise — particularly in cold, dry air.
    • Weather — cold air, sudden changes, thunderstorms.
    • Other conditions — allergic rhinitis and reflux can both worsen asthma.

    The practical move is not to avoid everything on that list. It is to find out which ones apply
    to you, which is what a simple record does better than memory.

    Keeping a useful trigger record

    For two to four weeks, note: the date and time of symptoms, what you were doing, where you were,
    the weather, and whether you needed your reliever. Patterns that are invisible day to day become
    obvious on a page — symptoms clustering on cold mornings, after vacuuming, at a particular
    workplace, or in one room of the house.

    Bring the record to your appointment. It is more useful than a recollection, and it moves the
    conversation from “how have you been?” to something specific.

    What actually reduces exposure

    Effectiveness varies a lot, and honesty is more useful than a long list.

    • Smoke. Eliminating tobacco smoke exposure in the home is among the highest-value
      changes available, for both children and adults.
    • Dust mites. Allergen-proof mattress and pillow covers and hot-washing bedding
      are the standard measures. Evidence that single measures alone improve asthma outcomes is mixed
      — combinations tend to do better than any one action.
    • Pets. Removing the animal is the effective measure, which for most households
      is not a realistic recommendation. Keeping pets out of the bedroom is the usual compromise.
    • Mould and damp. Fixing the moisture source matters more than cleaning the
      visible mould.
    • Pests. Cockroach allergen is a significant trigger in some housing; integrated
      pest management is the recommended approach.
    • Air quality. On poor air-quality days, reducing outdoor exertion is a
      reasonable, low-cost adjustment.

    Be sceptical of any product marketed as an asthma cure or as a replacement for medication. Air
    purifiers, supplements and breathing devices are sold heavily into this category, and none of them
    substitutes for a treatment plan.

    The asthma action plan

    An asthma action plan is a written document, agreed with your clinician, that tells you what to
    do as symptoms change — usually structured in zones:

    • Doing well — your usual routine.
    • Getting worse — specific steps, agreed in advance, and when to make
      contact.
    • Medical alert — the symptoms that mean urgent care now.

    Its value is that decisions get made calmly in advance rather than during an episode. If you do
    not have one, asking for one is a concrete, reasonable request.

    What to bring to your next appointment

    • Your trigger record.
    • How many rescue inhalers you have used in the past year.
    • How often you wake at night because of asthma.
    • Anything you have stopped doing because of your breathing — this is the one people most
      often leave out.
    • Your actual inhaler devices, so your technique can be watched — more than 8 in 10 people make at least one error.
    • Whether you have an action plan, and when it was last reviewed.

    When not to wait

    Seek urgent medical care for severe breathlessness, difficulty speaking in full sentences, a
    reliever that is not working or not lasting, or symptoms that are worsening quickly. Asthma is
    treatable, and it is also serious. If you are unsure whether a situation is an emergency,
    treat it as one.

    Sources

    MediVara publishes health journalism. This article is not medical advice and is not reviewed
    by a licensed clinician. Asthma treatment decisions, including any change to medication, belong
    with a qualified healthcare professional who knows your history.

    Frequently asked questions

    What does controlled asthma actually mean?

    Controlled asthma means asthma that is not limiting your life, assessed over roughly the past four weeks: daytime symptoms no more than twice a week, no night-time waking due to asthma, rescue-inhaler use no more than twice a week for symptoms, and no limitation on activity. It does not mean the asthma has gone away.

    What is the difference between asthma control and asthma severity?

    Control is how you are doing now. Severity is how much treatment it takes to get you there. Someone on substantial treatment with no symptoms has severe but well-controlled asthma. Someone on minimal treatment waking twice a week has mild but poorly controlled asthma. The second situation is the one that needs attention.

    How common is uncontrolled asthma?

    More common than most people assume. In US surveillance data, half of children with current asthma had uncontrolled asthma. Among adults with asthma, the proportion reporting an attack fell from 53.8 percent in 2001 to 39.6 percent in 2021, which is real improvement but still close to four in ten.

    What is the difference between a reliever and a controller inhaler?

    Relievers, or rescue inhalers, act quickly on symptoms and are for episodes. Controllers, typically inhaled corticosteroids, reduce the underlying airway inflammation over time and work whether or not you have symptoms today. Because the reliever produces an obvious immediate effect and the controller does not, it is easy to drift toward relying on the reliever. Needing a rescue inhaler often means the underlying inflammation is not controlled. Never change or stop prescribed medication without medical guidance.

    How do I find out what triggers my asthma?

    Keep a record for two to four weeks noting the date and time of symptoms, what you were doing, where you were, the weather, and whether you needed your reliever. Patterns that are invisible day to day become obvious on a page, such as symptoms clustering on cold mornings, after vacuuming, at a particular workplace, or in one room. Bring the record to your appointment.

    Related reading

  • Inhaler Technique: The Errors 8 in 10 People Make

    If your asthma feels less controlled than it should be, the problem may not be your medication. It
    may be how much of it is reaching your lungs.

    In a systematic review and meta-analysis of US studies, more than 8 out of 10 patients
    with obstructive lung diseases made at least one inhalation technique error     using a
    metered-dose inhaler. That is not a minority struggling. That is most people.

    The consequence is quiet and easy to miss: the dose is prescribed, the canister empties on
    schedule, the prescription is refilled, and a meaningful share of the drug never gets past the back
    of the throat. This article explains where technique breaks down, why those specific steps matter,
    and what to do about it. It is information, not medical advice, and it is not a substitute for
    having your own technique watched by a clinician or pharmacist.

    Where technique actually breaks down

    Errors are not evenly distributed across the process. Research measuring each stage found them
    concentrated like this:

    • Exhalation — 67.4% of patients made an error here. This is the single
      biggest failure point, and it happens before the inhaler is even fired.
    • Breathing in — 58.1%.
    • Breath hold — 51.2%.

    At least one in three patients have difficulty with each of three specific things: exhaling
    fully before inhalation, inhaling slowly and deeply, and holding their breath afterwards.

    Two errors stand out as the most common with pressurised metered-dose inhalers: failing
    to fire the inhaler while breathing in slowly    , and failing to hold the breath
    after the dose.

    Why each step exists

    These steps can feel like ritual. They are not. Each one is solving a specific physical problem.

    Exhale fully first — and away from the inhaler

    Your lungs cannot take in a deep, slow breath if they are already partly full. Skipping the
    exhale means the medication rides a shorter, shallower breath that does not carry it as deep into
    the airways. Breathing out into the device also adds moisture, which can affect dry-powder inhalers
    in particular.

    Inhale slowly, not hard

    This is the most counter-intuitive step, because the instinct with a metered-dose inhaler is to
    pull as hard as possible. Inhaling too fast is classified as a critical error — a
    peak inspiratory flow rate above roughly 90 litres per minute. A fast, turbulent breath throws the
    aerosol against the back of the throat instead of carrying it around the curve and down into the
    smaller airways.

    Slow and deep beats hard and fast. Note that dry-powder inhalers work on the opposite principle
    and generally do require a fast, forceful inhalation — which is exactly why a technique that
    works for one device can be wrong for another.

    Coordinate the press with the breath

    Poor actuation coordination — mistiming the release of the dose against the inhalation
    — is the other error classified as critical. Fire too early and the aerosol is already
    dispersing before the breath begins. Fire too late and much of the breath is over.

    This is genuinely difficult, and it is the single strongest argument for a spacer.

    Hold your breath afterwards

    Medication that reaches the small airways still needs time to settle onto the airway surface.
    Exhale immediately and a portion of it simply comes back out. The standard guidance is about ten
    seconds, or as long as is comfortable.

    Technique is also one of the two things worth ruling out before considering an asthma clinical trial, because a dose that never reaches the lungs makes any treatment look less effective than it is.

    The spacer question

    Not using a spacer with a metered-dose inhaler was found in 74.4% of patients.
    It is one of the most prevalent errors recorded, and one of the easiest to fix.

    A spacer is a holding chamber that sits between the inhaler and your mouth. It solves the
    coordination problem directly: the dose is released into the chamber, and you then breathe it in
    over the next few seconds rather than having to time the press and the breath to the same instant.
    It also slows the aerosol, so less of it lands in the throat.

    Spacers are widely recommended to improve delivery and reduce the coordination a good technique
    otherwise demands. If you have never been offered one and you use a metered-dose inhaler, it is a
    reasonable thing to raise.

    The standard metered-dose inhaler sequence

    This is the widely taught sequence. Devices differ, so treat it as orientation rather than
    instruction, and have your own device and technique checked in person.

    1. Remove the cap and check the mouthpiece is clear.
    2. Shake the inhaler.
    3. If the inhaler is new or has not been used for a while, prime it as the leaflet directs.
    4. Sit or stand upright.
    5. Breathe out fully, away from the inhaler.
    6. Seal your lips around the mouthpiece, or the spacer mouthpiece.
    7. Begin breathing in slowly, then press the canister once as the breath starts.
    8. Keep inhaling slowly and deeply until your lungs are full.
    9. Hold your breath for about ten seconds, or as long as is comfortable.
    10. Breathe out slowly, away from the inhaler.
    11. If a second dose is prescribed, wait as directed before repeating.
    12. If your inhaler contains a corticosteroid, rinse your mouth and spit afterwards.
      This reduces the risk of oral thrush and hoarseness.

    With a spacer, the difference is at steps 7 and 8: you press once into the chamber, then breathe
    in from it — either one slow deep breath and hold, or several normal breaths, depending on
    what you have been shown.

    Technique decays, even after you have been taught

    This is the finding that matters most for anyone who learned correctly years ago. Patients who
    initially demonstrate good technique after education get sloppy over time, taking
    shortcuts or reverting to old habits. Because of this, periodic review of inhaler technique is
    recommended.

    Being shown once is not durable. A yearly check is a reasonable default, and a review is
    particularly worth asking for if your device has changed, if your control has worsened, or if you
    are getting through rescue inhalers faster than before.

    How to get your technique checked

    • Ask your pharmacist. This is often the easiest route, requires no appointment
      at many pharmacies, and is exactly the setting where critical errors are routinely identified.
    • Bring your actual device. Not a description of it. Technique is
      device-specific, and advice for the wrong device type can be actively wrong.
    • Demonstrate rather than describe. Most people believe their technique is
      correct. Errors are found by watching, not by asking.
    • Ask specifically about the three weak points: your exhale, your inhalation
      speed, and your breath hold.
    • Ask whether a spacer is appropriate for you.
    • Ask for a re-check when anything changes — a new device, a new dose, or
      worsening symptoms.

    What this does and does not mean

    Better technique is not a substitute for a treatment plan, and none of this is a reason to change
    what you take. Do not adjust, stop or delay any prescribed medication based on an
    article.

    What it does mean is that if your asthma feels poorly controlled, technique is a genuinely common
    and genuinely fixable contributor that is worth ruling out early — before concluding that the
    medication itself is not working. It costs one conversation with a pharmacist.

    Worsening symptoms, increasing rescue-inhaler use, or night-time waking are reasons to contact your clinician, not reasons to wait and practise — they are also the specific signals that define whether your asthma is actually controlled.

    Sources

    MediVara publishes health journalism. This article is not medical advice and is not reviewed
    by a licensed clinician. Inhaler technique is device-specific and should be checked in person by a
    pharmacist or clinician. Never change or stop prescribed medication without medical guidance.

    Frequently asked questions

    What is the most common inhaler mistake?

    Errors cluster at the exhalation stage, where 67.4 percent of patients make a mistake, followed by breathing in at 58.1 percent and the breath hold at 51.2 percent. The two most commonly reported errors with pressurised metered-dose inhalers are failing to fire the inhaler while breathing in slowly, and failing to hold the breath after the dose.

    Should I breathe in fast or slow with an inhaler?

    With a metered-dose inhaler, slowly and deeply. Inhaling too fast is classified as a critical error, above roughly 90 litres per minute, because a fast turbulent breath throws the aerosol against the back of the throat instead of carrying it into the smaller airways. Dry-powder inhalers work on the opposite principle and generally do require a fast, forceful inhalation, which is why technique is device-specific.

    Do I really need a spacer?

    Not using a spacer with a metered-dose inhaler was recorded in 74.4 percent of patients and is one of the most prevalent errors found. A spacer solves the coordination problem directly: the dose is released into a holding chamber and you breathe it in over the next few seconds rather than timing the press and the breath to the same instant. If you use a metered-dose inhaler and have never been offered one, it is worth raising.

    How long should I hold my breath after using an inhaler?

    The standard guidance is about ten seconds, or as long as is comfortable. Medication that reaches the small airways needs time to settle onto the airway surface, so exhaling immediately means a portion of the dose simply comes back out.

    How often should my inhaler technique be checked?

    Periodic review is recommended, because technique decays. Patients who demonstrate good technique immediately after education get sloppy over time, taking shortcuts or reverting to old habits. A yearly check is a reasonable default, and a review is particularly worth asking for if your device has changed, your control has worsened, or you are using rescue inhalers faster than before. A pharmacist can watch your technique without an appointment at many pharmacies.

    Related reading

  • Private Health Screening: 10 Questions to Ask Before You Buy

    Direct-to-consumer health screening is now easy to buy. A package of ultrasound scans at a
    community venue, a blood panel ordered online, a whole-body MRI marketed as peace of mind —
    all available without a referral, usually for a fixed price.

    Start with what screening is and what the evidence supports if you have not already. This is a legitimate industry, and some of what it sells is genuinely useful to some people. It
    is also an industry where the marketing reliably foregrounds one half of the picture. This is a
    checklist for reading past the marketing, before you pay.

    First, separate the two things being sold

    A screening package bundles two different things: tests and the
    feeling of having done something responsible    . The second is what most of the advertising
    is actually about, and it is why packages are usually sold as bundles rather than as individual
    tests you choose.

    That matters commercially. A bundle priced as a unit obscures which components are recommended
    for someone with your age and risk profile, and which are there to make the package look
    comprehensive. Those are not the same tests.

    The ten questions

    1. Which of these specific tests is recommended for someone of my age and risk?

    National recommendations are bounded by age, sex and risk factors, because the balance of
    benefit and harm shifts between groups. If a ten-test package contains two that apply to you, that
    is worth knowing before you buy the ten. Ask the provider to say, test by test, which recommendation
    each one follows and which body issued it.

    2. What is the false-positive rate for these tests in people like me?

    A provider that cannot answer this, or treats it as an odd question, is telling you how it
    thinks about the service. For an uncommon condition in a low-risk population, most positive results
    will be false — this is arithmetic, not pessimism, and it is worked through here.

    3. What happens if something is found?

    This is the question that separates a health service from a test-selling operation. Does the
    provider arrange or coordinate follow-up? Does a clinician call you? Or does a report arrive for you
    to take somewhere else?

    There is no wrong answer here, but there is a wrong assumption. Many people buy a screening
    package believing follow-up is included when it is not.

    4. Who interprets the results, and what are their qualifications?

    Ask specifically: a radiologist, a physician, an algorithm, a technician? Are they licensed in
    your state? Will their name be on the report?

    5. What is the total cost, including follow-up?

    The advertised price is usually for the screening alone. A positive result leads to diagnostic
    testing, which is a separate cost and may or may not be covered by insurance — coverage rules
    differ for a self-ordered screen versus a clinically indicated test. Ask the provider what people
    typically end up spending when something is flagged.

    6. Will my regular clinician receive these results?

    If not, the findings live outside your medical record, and the person managing your care will
    not see them unless you carry them over yourself. That is manageable, but only if you know it in
    advance.

    7. Is this a subscription, and what are the renewal terms?

    Check before, not after. Find the cancellation path before you sign up, not when you want to
    leave.

    8. What happens to my health data?

    This deserves more weight than it usually gets. A self-ordered screening service may not sit
    inside the same regulatory framework as your doctor’s office. Ask directly: is my data sold or
    shared with third parties, is it used for marketing, can I have it deleted, and what happens to it
    if the company is acquired or closes? Read the privacy policy rather than the reassurance on the
    landing page.

    9. What are the risks of the tests themselves?

    Most screening tests are low-risk, but not all are zero-risk, and some involve radiation
    exposure. A provider should be able to state this plainly without defensiveness.

    10. What would you say to someone who decided not to do this?

    A good provider can answer this calmly, because for many people not screening is a reasonable
    choice. An answer built on fear tells you what the service is optimised for.

    Marketing patterns worth noticing

    None of these prove a service is bad. All of them are reasons to slow down.

    • Urgency and countdowns. Screening decisions are not time-critical. A deadline
      on the price is a sales mechanism, not a medical one.
    • “Everyone should be tested.” No major recommendation says this about anything.
      Recommendations are bounded by design.
    • Anecdote as evidence. A story about a life saved by an early finding is real
      and moving, and it says nothing about how the test performs across everyone who took it. The people
      who were harmed by a false alarm do not appear in testimonials.
    • Comprehensiveness framed as a benefit in itself. More tests means more results,
      which means more false positives and more incidental findings. Breadth is not automatically better.
    • No mention of downsides anywhere. Screening has well-documented harms. A
      provider that discusses none of them has made an editorial choice.
    • Pressure to add tests at the venue. Decide what you are buying before you
      arrive.

    When a screening package is the wrong tool entirely

    If you have a symptom, you do not need screening — you need a diagnosis.
    Screening is designed for people without symptoms, and a self-ordered panel is a detour. A
    persistent or worrying symptom warrants a clinician directly.

    The same applies if you have a family history of a specific condition or an existing condition
    under management. Those situations call for targeted advice about which tests apply to you, which a
    standard package cannot provide because it does not know anything about you.

    A reasonable way to decide

    1. Find out which screenings are recommended for your age and risk profile.
    2. Ask whether your existing healthcare covers them — in the US, many recommended preventive
      services are covered without cost-sharing, which can make a paid package redundant.
    3. If you still want a private package, price the recommended tests individually against the
      bundle.
    4. Ask the ten questions above and note which ones the provider answers plainly.
    5. Decide when you are not under time pressure.

    Screening can be worth doing. The point of this checklist is that it should be a decision you
    made, not a package you were sold.

    Sources

    MediVara publishes health journalism. This article is not medical advice, is not reviewed by
    a licensed clinician, and does not endorse or recommend any screening provider. Which screenings
    are appropriate for you is a question for a qualified healthcare professional.

    Frequently asked questions

    Are private health screening packages worth it?

    It depends on which tests are in the package and whether they are recommended for your age and risk profile. A bundle priced as a unit obscures which components apply to you and which are there to make the package look comprehensive. Ask the provider to say, test by test, which recommendation each one follows. In the US, many recommended preventive services are already covered by insurance without cost sharing, which can make a paid package partly redundant.

    Is a whole-body MRI scan a good idea for a healthy person?

    No major clinical body recommends whole-body MRI as routine screening for people without symptoms. The central problem is incidental findings: broad imaging frequently detects something unrelated to what was being looked for, most of which turns out not to matter, but separating the significant from the harmless means further scans, sometimes biopsies, and a period of monitoring.

    Will my insurance cover a private screening package?

    Often not, and the rules can differ between a self-ordered screen and a clinically indicated test. The bigger surprise is usually follow-up: the advertised price normally covers the screening alone, and a positive result leads to diagnostic testing that is billed separately. Ask what people typically end up spending when something is flagged.

    What happens to my health data if I use a private screening service?

    Ask directly, and read the privacy policy rather than the reassurance on the landing page. A self-ordered screening service may not sit inside the same regulatory framework as your doctor’s office. The questions that matter are whether your data is sold or shared with third parties, whether it is used for marketing, whether you can have it deleted, and what happens to it if the company is acquired or closes.

    Should I buy a screening package if I have a symptom?

    No. Screening is designed for people without symptoms. If you have a symptom you are looking for a diagnosis, and a self-ordered panel is a detour that can delay it. A persistent or worrying symptom warrants a clinician directly.

    Related reading

  • False Positives and Overdiagnosis: How to Read a Test Result

    A test result arrives and it says something unexpected. The immediate reaction is almost always to
    treat it as a fact about your body. Often it is not — or not yet. It is a probability
    statement, and how likely it is to be right depends heavily on something the result itself does not
    tell you: how common the condition is among people like you.

    This is a companion to our guide to what preventive screening is and what it can miss. It explains why tests are wrong more often than most people expect, what overdiagnosis
    means and why it is the hardest harm to see, and how to read a result without either panicking or
    dismissing it.

    No test is a yes-or-no machine

    Every test has two ways of being wrong.

    • A false positive says something is there when it is not.
    • A false negative says nothing is there when something is.

    These are not defects in a badly made test. They are properties of every test, because tests
    measure a proxy — a chemical level, a density on an image, an electrical pattern — and
    the ranges for people with and without a condition always overlap somewhat.

    Two terms describe how a test handles that overlap:

    • Sensitivity — how good it is at catching people who do have the
      condition. High sensitivity means few false negatives.
    • Specificity — how good it is at clearing people who do not. High
      specificity means few false positives.

    The two trade off against each other. A test tuned to miss almost nobody will flag more healthy
    people; one tuned to avoid false alarms will miss more real cases. Where a test is set on that dial
    is a deliberate design choice, not an accident.

    Why a positive result on a rare condition is usually wrong

    This is the part that is genuinely counter-intuitive, and it is the single most useful idea in
    this article.

    Imagine a test with 99% specificity — it wrongly flags only 1 in 100 healthy people. That
    sounds excellent. Now apply it to 10,000 people for a condition that affects 1 in 1,000.

    • About 10 people actually have the condition. A good test finds most of them — say 9.
    • About 9,990 do not. One per cent of them are wrongly flagged — about 100 people.

    So roughly 109 people get a positive result, and only 9 of them have the condition. More
    than 90% of the positives are false     — from a test that is 99% specific.

    Nothing is wrong with the test. The arithmetic is driven by how rare the condition is. This is
    why testing a broad, low-risk population for an uncommon condition produces a flood of false alarms,
    and why the same test used in people with symptoms or known risk factors performs far better: in
    that group, the condition is more common to begin with, so a positive result carries more weight.

    It is also the mathematical reason screening guidelines are bounded by age and risk rather than offered to everyone.

    Overdiagnosis: the harm that does not look like one

    Overdiagnosis is different from a false positive, and the distinction matters.

    • A false positive finds something that is not there.
    • Overdiagnosis finds something that is there, correctly, but that would
      never have caused symptoms or shortened your life.

    The finding is real. The biopsy confirms it. Nobody made a mistake. And yet treating it delivers
    no benefit, while carrying every ordinary risk of treatment — surgery, medication, side
    effects, cost, and the permanent status of being a patient.

    Overdiagnosis is hard to see because it is invisible at the individual level. A person who is
    overdiagnosed and treated appears to be a success story: something was found, it was treated, they
    are fine. Nobody can know they would have been fine anyway. The phenomenon is only visible in
    population data — when a screening programme finds far more cases than ever went on to cause
    harm before screening existed.

    Because you cannot tell in advance which findings would have stayed harmless, overdiagnosis is
    genuinely difficult to avoid rather than simply careless. It is a real cost of screening that an
    honest account has to include.

    Incidental findings

    Broad imaging frequently finds something unrelated to what was being looked for — a nodule,
    a cyst, an anatomical variation. A minority matter. Most do not. But separating the two usually
    means more scans, sometimes a biopsy, and a period of monitoring.

    The clinical term for a small, probably harmless finding of uncertain significance is sometimes
    half-jokingly called an incidentaloma. The joke reflects a real problem: once something is
    on a record, it is difficult to leave alone, even when leaving it alone is the right answer.

    Reading your own results without spiralling

    A positive screening result is not a diagnosis. It is a reason to do a
    diagnostic test. The screening result opens the question; something else closes it.

    A normal result is reassurance, not a guarantee. False negatives exist. If a
    symptom appears later, a clear test from before does not answer it — and it is not a reason
    to wait.

    A number outside the reference range is not automatically abnormal. Reference
    ranges are usually set so that a percentage of healthy people fall outside them by definition. On a
    panel of twenty measurements, at least one falling outside its range is the expected outcome, not a
    surprise.

    Trend usually beats a single reading. One blood pressure measurement in a
    clinic is weak evidence; a series taken over time in ordinary conditions is much stronger. This is
    precisely why national guidance recommends confirming raised blood pressure outside the clinical
    setting before starting treatment.

    Questions worth asking about any result

    • Is this a screening test or a diagnostic test?
    • Given my age and risk, how likely is it that this positive result is real?
    • What is the next step to confirm or rule it out, and how long will it take?
    • What happens if we do nothing and repeat the test later?
    • If this is confirmed, does treating it change my outcome — or only my paperwork?
    • Is this finding what we were looking for, or something we found along the way?

    That fifth question is the one most worth asking, and the one least often asked.

    What to take from this

    • Every test has false positives and false negatives; this is design, not failure.
    • For an uncommon condition in a low-risk population, most positive results are false —
      even from a very specific test.
    • Overdiagnosis means correctly finding something that would never have harmed you, and it is
      invisible in any individual case.
    • A positive screening result opens a question; a diagnostic test closes it.
    • A normal result does not override a symptom that appears afterwards.
    • Trends are more informative than single readings.
    • Before buying a screening bundle, work through the ten questions.

    Sources

    MediVara publishes health journalism. This article is not medical advice and is not reviewed
    by a licensed clinician. Interpreting your own test results is something to do with a qualified
    healthcare professional who knows your history.

    Frequently asked questions

    Does a positive screening result mean I have the disease?

    No. A positive screening result means your risk is higher than it was before the test, and that a diagnostic test is warranted. For an uncommon condition in a low-risk population, the majority of positive screening results turn out to be false. The screening result opens the question; a diagnostic test closes it.

    Why are false positives so common?

    Because of how rare the condition is, not because the test is bad. Take a test that wrongly flags only 1 percent of healthy people, applied to 10,000 people for a condition affecting 1 in 1,000. Around 10 people have it and about 9 are found. Of the 9,990 who do not, 1 percent are wrongly flagged, which is about 100 people. So roughly 109 positives appear and only 9 are real. Over 90 percent are false, from a test that is 99 percent specific.

    What is overdiagnosis?

    Overdiagnosis is correctly finding a real abnormality that would never have caused symptoms or shortened your life. It differs from a false positive, where nothing is there at all. The finding is genuine, but treating it provides no benefit while carrying the usual risks of treatment. It is invisible in any individual case, because nobody can know that a treated person would have been fine anyway.

    What is the difference between sensitivity and specificity?

    Sensitivity is how well a test catches people who do have the condition, so high sensitivity means few false negatives. Specificity is how well it clears people who do not, so high specificity means few false positives. The two trade off against each other, and where a test sits on that dial is a deliberate design choice.

    Should I worry about one abnormal number on a blood panel?

    Not necessarily. Reference ranges are typically set so that a percentage of healthy people fall outside them by definition. On a panel of twenty measurements, at least one result outside its range is the expected outcome rather than a surprise. A trend across several readings is far more informative than a single value.

    Related reading

  • How Clinical Trials Work and How to Check One Is Real

    Most people first hear about clinical trials at a moment when they least want to be researching
    anything — after a diagnosis, or while a treatment is not working. The information that turns
    up is often either a dense research protocol or a recruitment page that wants your phone number.
    Neither explains the thing you actually need to know first: what a trial is, whether you can join
    one, and what joining involves.

    This is a plain explanation of how clinical trials work in the United States, how eligibility is
    decided, and how to check that a study you have found is real. It is information, not medical
    advice, and MediVara does not screen, endorse or recommend any specific trial.

    What a clinical trial actually is

    A clinical trial is a research study in which people volunteer to help answer a specific medical
    question — whether a treatment works, how safe it is, or how it compares with existing care.
    The key word is research. A trial is not a treatment programme, and it is not a way to get
    care that has already been shown to work. It exists because the answer is genuinely not yet known.

    That uncertainty is the point, and it is also the main thing to understand before joining one.
    If the answer were known, there would be no trial.

    The four phases

    Drug and device trials are usually described in phases. Each phase is designed to answer a
    narrower question in as few participants as possible.

    • Phase 1 — a small group. The question is mainly safety and dosage: what
      happens in people, and at what dose.
    • Phase 2 — a larger group. Does it appear to work, and what side effects
      show up more clearly at scale?
    • Phase 3 — larger still, often across many sites. How does it compare
      with existing standard treatment? This is typically the evidence regulators rely on.
    • Phase 4 — after approval. Long-term effects, rarer side effects, and
      performance in wider everyday use.

    Not every study fits this ladder. Observational studies, registries and behavioural or screening
    studies ask different questions and may involve no new drug at all.

    Eligibility: why trials turn people away

    Every study publishes eligibility criteria — the requirements a person
    must meet to take part. They come in two kinds:

    • Inclusion criteria — what you must have. A specific diagnosis, an age
      range, a test result within a certain band.
    • Exclusion criteria — what rules you out. Another condition, a medication
      that would interfere, a previous treatment, pregnancy.

    Being excluded is not a judgement about you, and it is common. Criteria exist so the study can
    answer its question cleanly and so participants are not exposed to avoidable risk. A study of one
    condition that admitted people with a second, interacting condition would produce a result nobody
    could interpret.

    The practical consequence: expect to be screened out of most studies you look at.
    People who eventually enrol have usually contacted several.

    Informed consent is a process, not a signature

    Before you join anything, the study team must take you through informed consent
    — learning and discussing the details, including the risks and potential benefits, before you
    decide whether to take part. It is the main way people get study information before deciding.

    Some things worth knowing about it:

    • It is a conversation, and you can take the document away and read it with someone else.
    • Signing it does not commit you. You can withdraw from a study at any time, for
      any reason, without giving one.
    • If the study changes materially, you should be re-consented.

    If a recruiter pushes you to sign quickly, that is a reason to slow down, not to hurry.

    Who oversees a study

    US studies are reviewed by an Institutional Review Board (IRB) — a group
    that reviews, approves and monitors the study protocol, and whose role is to protect the rights
    and welfare of participants, including by reviewing the informed consent form. An IRB deliberately
    includes people from varying backgrounds, among them a community member, so that review is not
    conducted only by researchers.

    Separately, ClinicalTrials.gov is the
    public registry maintained by the US National Institutes of Health. Under
    FDAAA 801 and the
    Final Rule    , certain trials are legally required to register and to report results — which
    is what makes the registry a genuine verification tool rather than an advertising channel.

    How to check that a study is real

    Many trials recruit through third-party websites and ad campaigns. Some of these are run by
    legitimate recruitment firms working for a study sponsor. The site itself is not the study, and
    seeing a polished page tells you nothing either way.

    A practical verification sequence:

    1. Get the NCT number. Every registered study has one, in the form
      NCT followed by eight digits. A legitimate recruiter can give it to you.
    2. Look it up on ClinicalTrials.gov directly — type the address yourself
      rather than following a link you were sent.
    3. Compare what you were told with the registry record: the condition, the phase,
      the eligibility criteria, the recruiting status and the listed locations.
    4. Check who the sponsor is, and whether a site near you is actually recruiting.
    5. Ask what happens to your data if you are screened out. A recruitment form is a
      disclosure of health information, and you are entitled to know where it goes.

    Warning signs worth taking seriously: no NCT number available on request, a promise of
    guaranteed acceptance, a request for payment to participate, pressure to decide immediately, or a
    claim that the study will cure a condition. Research does not make guarantees, and legitimate
    studies do not charge participants to enrol.

    Questions to ask the study team

    • What is the purpose of this study, and what phase is it?
    • What will I be asked to do, how often, and for how long?
    • What are the known risks and side effects so far?
    • What tests will I have, and how should I interpret the results?
    • Is there a placebo group? If so, what does the placebo group receive — nothing, or
      standard care plus placebo?
    • Will I be told which group I am in, and when?
    • What happens to my regular treatment while I am enrolled?
    • Who pays for what? Research procedures are commonly covered by the sponsor, but routine care
      costs may still be billed — ask specifically.
    • Are travel or time costs reimbursed?
    • What happens when the study ends? Can I keep taking the treatment if it helped?
    • Who do I contact if something goes wrong, at any hour?
    • Will the results be shared with me?

    For a worked example in one condition, see our guide to asthma clinical trials and how to decide whether to join.

    Weighing it up honestly

    People join trials for two broad reasons: access to something not otherwise available, and
    contributing to knowledge that helps others later. Both are legitimate. Participants also often
    receive close monitoring, simply because a study measures things carefully.

    Against that: the treatment may not work, you may receive a placebo or the comparison treatment,
    there may be side effects that are not yet known, and the schedule of visits and tests is usually
    more demanding than ordinary care. A trial is a genuine contribution and a genuine commitment, and
    it is reasonable to decline one.

    Discuss any trial with the clinician who manages your care before enrolling.
    They know your history, your current treatment and how a study schedule would interact with it
    — none of which a recruitment form can see.

    Sources

    MediVara publishes health journalism. This article is not medical advice, is not reviewed by
    a licensed clinician, and MediVara does not screen, endorse or recommend any specific clinical
    trial or recruitment service. Decisions about trial participation should be made with a qualified
    healthcare professional.

    Related reading

  • Preventive Health Screening: What It Is and What It Can Miss

    Screening means testing for a disease before you have symptoms. That single distinction
    explains most of the confusion around health checks — and most of the disappointment people
    feel when a test does not deliver what they expected.

    This guide covers what screening is, what the evidence currently supports, where it genuinely
    helps, where it causes harm, and what to ask before paying for a screening package. It is
    information, not medical advice, and it is not a substitute for a conversation with a clinician
    who knows your history.

    Screening and diagnostic testing are not the same thing

    They use similar machines and often the same lab, but they answer different questions.

    • Screening asks: you feel fine — is there anything here we should look at?
      It is applied to large groups of people who have no symptoms.
    • Diagnostic testing asks: you have a symptom or an abnormal result — what is
      causing it?       It is applied to one person with a specific question.

    This matters for a practical reason. A screening test that returns something unexpected does not
    give you a diagnosis. It gives you a reason to do a diagnostic test, which is why a positive screening result is not a diagnosis. The screening result is the
    beginning of the process, not the end of it.

    Why recommendations differ by age and risk

    In the United States, the U.S. Preventive Services Task Force
    (USPSTF) reviews the evidence for preventive services and assigns each one a grade. Those grades rest on evidence from clinical trials and other research studies.
    Grade A and Grade B mean the Task Force found a high or moderate
    net benefit — benefit after harms are subtracted.

    Examples of current Grade A and B recommendations for adults:

    • Colorectal cancer — screening for adults aged 50 to 75 (Grade A), and
      aged 45 to 49 (Grade B).
    • Breast cancer — in April 2024 the USPSTF lowered the starting age,
      recommending screening mammography every two years beginning at age 40.
    • Blood pressure — screening for adults aged 18 and over, with
      measurements taken outside the clinical setting to confirm a diagnosis before treatment starts.
    • Hepatitis C — one-time screening for adults aged 18 to 79 (Grade B).
    • HIV — routine screening for adolescents and adults (Grade A).
    • Abdominal aortic aneurysm — one-time ultrasound for men aged 65 to 75
      who have ever smoked (Grade B).

    Notice the pattern. Every recommendation is bounded — by age, by sex, by smoking history,
    by frequency. That is not bureaucratic caution. It is the evidence saying that the same test
    produces a different balance of benefit and harm in different people.

    The AAA recommendation is the clearest illustration: one ultrasound, for men in a ten-year age
    window, who have smoked. Outside that group, the evidence does not support the same conclusion.

    The part most screening marketing leaves out

    Screening has real costs, and they are not only financial. Any honest account includes them.

    False positives

    A test says something is there when nothing is. What follows is a diagnostic work-up —
    more tests, sometimes a biopsy, and a period of waiting that people consistently describe as
    distressing. The anxiety is not a footnote; for many people it is the main harm they actually
    experience.

    False negatives

    A test says nothing is there when something is. The risk here is a false sense of security
    — a clear screening result is not a guarantee of health, and it is not a reason to ignore a
    symptom that appears later.

    Overdiagnosis

    This one is the least intuitive and the most important. Overdiagnosis means correctly finding a
    real abnormality that would never have caused symptoms or shortened your life. The finding is not
    a mistake — it is genuinely there. But treating it delivers no benefit while carrying all the
    usual risks of treatment. Because you cannot tell in advance which findings would have stayed
    harmless, this is difficult to avoid rather than simply careless. The arithmetic behind this, and behind false positives generally, is covered in how to read a test result.

    Incidental findings

    Broad imaging often finds something unrelated to what was being looked for. Some of it matters.
    Much of it does not, and sorting one from the other takes time, money and further testing.

    Why “more testing” is not automatically better

    It is intuitive to think that more information can only help. Screening is one of the places
    where that intuition breaks down, because every test carries a probability of being wrong in both
    directions, and because finding something is not the same as benefiting from finding it.

    This is precisely why recommendations specify who should be screened and how often. A guideline
    that says “adults aged 45 to 75” is not withholding a benefit from a 30-year-old. It reflects
    evidence that in a 30-year-old, the same test would produce more harm than good.

    Evaluating a private screening service

    Private screening — often a bundle of ultrasound scans and blood tests offered directly to
    consumers — is a legitimate industry. It is also one where the marketing usually foregrounds
    benefit and says little about the harms above.

    Questions worth asking before you pay — covered at greater length in our ten-question checklist for screening packages:

    • Which of these tests is recommended for someone with my age and risk profile?
      If a package contains ten tests and two are recommended for you, that is worth knowing before you
      buy the package.
    • What happens if something is found? Does the service arrange follow-up, or
      does the result arrive by post for you to take to a clinician?
    • Who interprets the results, and what are their qualifications?
    • What is the false-positive rate for these specific tests? A service that
      cannot answer this is worth a second look.
    • What is the total cost, including any follow-up? The advertised price is
      often for the screening alone.
    • Will my regular clinician receive these results?
    • Is this a subscription? Check the renewal terms before, not after.

    A service that answers these plainly is behaving well. One that responds with urgency,
    countdowns or claims that everybody should be tested is telling you something about its priorities.

    When to talk to a clinician instead

    Screening is for people without symptoms. If you have a symptom, you are not looking for
    screening — you are looking for diagnosis    , and a self-ordered screening panel is the
    wrong tool. A persistent or worrying symptom warrants a clinician, not a test bundle.

    A conversation is also the better starting point if you have a family history of a specific
    condition, a chronic condition already under management, or if you simply are not sure which
    recommendations apply to you. Risk-based screening decisions depend on details that a package
    cannot know about you.

    What to take from this

    • Screening tests people without symptoms; diagnostic testing investigates a specific question.
    • Recommendations are bounded by age and risk because the benefit–harm balance shifts
      between groups.
    • USPSTF Grade A and B means high or moderate net benefit — benefit after harms.
    • False positives, false negatives, overdiagnosis and incidental findings are ordinary outcomes,
      not rare failures.
    • A normal result is reassurance, not a guarantee.
    • Before buying a screening package, ask which tests actually apply to you and what happens next
      if something is found.
    • Symptoms call for a clinician, not a screening panel.

    Sources

    MediVara publishes health journalism. This article is not medical advice and is not reviewed
    by a licensed clinician. Screening decisions depend on your individual history and risk —
    discuss them with a qualified healthcare professional.

    Frequently asked questions

    What is the difference between a screening test and a diagnostic test?

    A screening test looks for evidence of disease in someone who has no symptoms. A diagnostic test is used when symptoms or an abnormal result are already present, to find out what is causing them. Screening tests are usually less invasive and carry little risk of complications; diagnostic tests, such as a biopsy, can be more invasive and carry a small risk. A positive screening result indicates increased risk, not a diagnosis.

    At what age should I start screening?

    It depends entirely on the test and on your risk factors. The USPSTF recommends colorectal cancer screening from age 45, breast cancer screening every two years from age 40, blood pressure screening from age 18, one-time hepatitis C screening for adults aged 18 to 79, and a one-time abdominal aortic aneurysm ultrasound for men aged 65 to 75 who have ever smoked. There is no single starting age for screening in general.

    Does a normal screening result mean I am healthy?

    No. A normal result is reassurance, not a guarantee. False negatives exist, and a clear result from a previous test does not answer a symptom that appears later. If you develop a symptom, that warrants attention regardless of past results.

    Is more screening always better?

    No, and this is the least intuitive part of screening. Every test has a chance of being wrong in both directions, and finding something is not the same as benefiting from finding it. Broader testing produces more false positives, more incidental findings and more overdiagnosis. This is why recommendations specify who should be screened rather than recommending everything for everyone.

    Are recommended screenings covered by insurance in the US?

    Under the Affordable Care Act, most non-grandfathered health plans must cover preventive services rated A or B by the USPSTF without cost sharing when delivered in network. Coverage rules can differ for a self-ordered screening or for follow-up diagnostic testing after an abnormal result, so it is worth confirming with your plan before assuming a cost is covered.

    Related reading

  • Vaccine Technology: How mRNA Changed Modern Immunology Forever

    Vaccine Technology: How mRNA Changed Modern Immunology Forever

    The mRNA Platform: Speed and Precision

    Before COVID-19, messenger RNA vaccines existed only in research laboratories. Within eighteen months of the SARS-CoV-2 sequence being published, mRNA vaccines had completed Phase 3 trials and received emergency authorization. This unprecedented timeline — compared to the typical decade-plus vaccine development process — demonstrated the transformative potential of the platform.

    Traditional vaccines use weakened viruses, inactivated pathogens, or protein subunits to train immune systems. mRNA vaccines work differently: they deliver genetic instructions that prompt cells to temporarily produce a target protein, which the immune system then learns to recognize. No live pathogen is involved, and the mRNA degrades within days. The immune memory it creates, however, persists for years.

    The key innovation making this possible came from decades of basic research by Katalin Karikó and Drew Weissman, who discovered in 2005 that chemically modifying nucleosides in mRNA prevented the inflammatory immune response that had previously made mRNA therapeutics impractical. This discovery, which earned the 2023 Nobel Prize in Physiology or Medicine, unlocked the entire platform.

    Vaccine research

    Beyond COVID: The Pipeline of mRNA Vaccines and Therapeutics

    The COVID vaccines proved the concept at massive scale, but the mRNA pipeline extends far beyond respiratory viruses. RSV vaccines using the mRNA platform have now been approved, offering better protection than protein-subunit alternatives. Influenza mRNA vaccines in Phase 3 trials have shown improved efficacy over traditional flu shots, potentially solving the annual formulation problem by enabling faster updates to match circulating strains.

    Personalized cancer vaccines represent the most ambitious application. By sequencing a patient’s tumor and identifying mutations unique to their cancer (neoantigens), researchers can design a customized mRNA vaccine within weeks. A landmark 2023 New England Journal of Medicine study showed that a personalized mRNA vaccine combined with immunotherapy reduced melanoma recurrence by 44% compared to immunotherapy alone in a Phase 2b trial.

    HIV has resisted vaccine development for 40 years due to its extreme mutation rate and ability to hide in immune cells. The mRNA platform offers new strategies: by targeting conserved viral regions or training multiple arms of the immune system simultaneously, researchers hope to overcome barriers that defeated previous approaches. Phase 1 trials of mRNA-based HIV vaccines are now in progress.

    Vaccine development

    Safety, Surveillance, and Long-Term Evidence

    With over two billion mRNA COVID vaccine doses administered globally, the safety profile is now among the best-characterized of any vaccine in history. The most serious identified risk — myocarditis, primarily in young males after the second Moderna dose — occurs at a rate of approximately 22 per million doses and in the vast majority of cases is mild and self-resolving. Population-level data consistently show that vaccine risks are dwarfed by COVID infection risks.

    Vaccine pharmacovigilance systems developed and stress-tested during COVID provide a template for monitoring future mRNA products. The FDA’s Vaccine Adverse Event Reporting System (VAERS), CDC’s Vaccine Safety Datalink, and international equivalents detected myocarditis signal within weeks of large-scale rollout — demonstrating that safety surveillance systems can identify even rare adverse events rapidly.

    Questions about mRNA vaccine durability led to development of updated boosters targeting new variants. Research on next-generation mRNA vaccine formulations focuses on improving lipid nanoparticle delivery vehicles for stability at room temperature (eliminating cold-chain requirements), extending immune durability, and developing mucosal vaccines that prevent infection at the point of entry.

    Immunology research

    The Future of mRNA Medicine

    Beyond vaccines, mRNA therapeutics are advancing for metabolic diseases, rare genetic disorders, and organ repair. Moderna and others are developing mRNA-encoded replacement proteins for conditions like methylmalonic acidemia, where a single missing enzyme causes severe metabolic disease. By delivering mRNA directly to the liver, patients may receive a regular “dose” of the enzyme they cannot produce.

    mRNA-mediated in vivo gene editing is another frontier — rather than permanently altering the genome, periodic mRNA doses could provide therapeutic effects while preserving reversibility. This approach may offer a middle path between permanent gene editing and the limitations of traditional drugs. The regulatory and manufacturing infrastructure built for mRNA vaccines is now accelerating development across this entire therapeutic class.

    KEY TAKEAWAYS

    • COVID mRNA vaccines went from sequence to authorization in 18 months, a record
    • The Nobel Prize-winning mRNA modification discovery dates to 2005
    • Personalized cancer mRNA vaccines reduced melanoma recurrence by 44% in trials
    • Over 2 billion mRNA doses provide the most comprehensive vaccine safety dataset ever
    • RSV mRNA vaccines outperform protein-subunit alternatives already approved
    • Room-temperature stable mRNA vaccines would eliminate cold-chain barriers globally

    Related reading